[Form 4] Corcept Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Global Net Lease, Inc. (GNL) – Form 4 insider transaction

Director Portia Sue Perrotty acquired 4,667 common shares on 07/01/2025. The shares were issued at an indicated value of $7.55 each under the company’s 2025 Omnibus Incentive Compensation Plan, replacing a portion of her annual cash retainer for board and committee service.

After the grant, the director’s directly held stake increases to 115,661 shares. No shares were sold and no derivative securities were involved.

• Transaction code: A (award/award-related acquisition)
• Estimated grant value: ≈ $35,000 (4,667 × $7.55)
• Ownership classification: Direct

The award modestly deepens insider equity alignment but, being compensation-related rather than an open-market purchase, carries limited market-moving weight.

Positive

• Director increased direct ownership to 115,661 shares, demonstrating some alignment with shareholder interests.

Negative

• Grant is part of routine compensation rather than an open-market purchase, limiting its signaling power and market impact.

Insights

Equity Research Analyst

TL;DR: Small, compensation-based stock grant; negligible valuation impact.

The 4,667-share award lifts the director’s holdings by roughly 4% to 115,661 shares. At ≈ $35k, the dollar value is immaterial relative to GNL’s market capitalization and does not reflect an active buy decision—thus signaling value is muted. Because the transaction is part of routine board compensation, the filing is best viewed as neutral for investors.

Corporate Governance Specialist

TL;DR: Stock-in-lieu-of-cash retainer modestly improves board-shareholder alignment.

Opting to receive equity instead of cash suggests the director prefers ownership participation, aligning her interests with shareholders. While modest in size, such elections cumulatively promote long-term stewardship and are incrementally positive for governance quality. Nevertheless, the absence of open-market buying tempers the strength of any bullish signal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maduck Sean

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		M		205	A	$5.05	17,910(1)	D
Common Stock	07/01/2025		S(2)		205	D	$73.4523(3)	17,705(1)	D
Common Stock								89,693	I	See Footnote(4)
Common Stock								10,000	I	See Footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.05	07/01/2025		M			205	(6)	05/02/2026	Common Stock	205	$0	61,781	D

Explanation of Responses:

1. Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.62 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

5. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

6. Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider involved in GNL's latest Form 4?

Portia Sue Perrotty, a director of Global Net Lease, Inc.

How many GNL shares were acquired in the transaction?

The director received 4,667 common shares.

What was the reported price per share for the award?

The Form 4 lists an indicative price of $7.55 per share.

What is the director's total GNL shareholding after the grant?

Her direct ownership increases to 115,661 shares.

Was this an open-market purchase by the director?

No. The shares were issued under the 2025 Omnibus Incentive Compensation Plan as part of the annual retainer.

Did the filing disclose any derivative security activity?

No derivative securities were acquired or disposed of in this filing.